Usana Health Sciences, Inc., a Utah-based nutritional, skincare and dietary products manufacturer, indicates in its recently filed 8-K that it has substantially completed an internal investigation into whether the expense reimbursement policy and other practices at its Chinese affiliate, BabyCare Ltd., were compliant with the Foreign Corrupt Practices Act. The company reports that it is cooperating with the DOJ and the SEC in their investigations of the matter.
February 5, 2019
DOJ and SEC investigating nutritional supplement maker for possible FCPA violations
Related by Topic
New Post
DOJ issues declination with disgorgement letter to Boston Consulting Group for possible FCPA offenses
August 29, 2024
News Alert
New Post
Former oil and gas trader pleads guilty to additional FCPA charges
August 23, 2024
News Alert
Smartmatic executives indicted for money laundering and FCPA violations
August 12, 2024
News Alert